Annual license maintenance fee payable.

No definition available.

Name:	ovid_AnnualLicenseMaintenanceFeePayable
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration and Option Agreement, Research Plan And Budget, Expected Costs

+ References

No definition available.

+ Details

Name:	ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Common Stock Issuance , Period Immediately Preceding Execution Date

+ References

No definition available.

+ Details

Name:	ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate
Namespace Prefix:	ovid_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Consideration payable for rights grant.

+ References

No definition available.

+ Details

Name:	ovid_ConsiderationPayableForRightsGrant
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

First payment due upon completion of first phase.

+ References

No definition available.

+ Details

Name:	ovid_FirstPaymentDueUponCompletionOfFirstPhase
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Gain On Recovery Of Fraudulent Funds Transfer

+ References

No definition available.

+ Details

Name:	ovid_GainOnRecoveryOfFraudulentFundsTransfer
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement, Development Milestone Approvals, Product Threshold

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold
Namespace Prefix:	ovid_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Global commercial and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementMilestonePayments
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License Agreement, Termination, Advance Notice Period

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementTerminationAdvanceNoticePeriod
Namespace Prefix:	ovid_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum number of product covered under license agreement

+ References

No definition available.

+ Details

Name:	ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement
Namespace Prefix:	ovid_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Obligation, Term

+ References

No definition available.

+ Details

Name:	ovid_RoyaltyObligationTerm
Namespace Prefix:	ovid_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Cash Payment

+ References

No definition available.

+ Details

Name:	ovid_UpfrontCashPayment
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront non-creditable one-time license issuance fee payment.

+ References

No definition available.

+ Details

Name:	ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (j)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-22

+ Details

Name:	us-gaap_LossContingencyLossInPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow associated with the purchase of all investments (debt, security, other) during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GensaicIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ovid_AstrazenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ovid_GensaicIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES (Details)	1 Months Ended					3 Months Ended			6 Months Ended
COMMITMENTS AND CONTINGENCIES (Details)	Jan. 31, 2025 USD ($)	May 31, 2023 USD ($)	Aug. 31, 2022 USD ($) product	Dec. 31, 2021 USD ($)	Dec. 31, 2016 USD ($) product	Jun. 30, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) shares	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) shares
Loss Contingencies [Line Items]
Common stock shares issued (in shares) \| shares						71,109,514			71,109,514		71,009,866
Prepaid expenses and other current assets						$ 3,742,000			$ 3,742,000		$ 2,865,000
Research and development						6,465,000		$ 12,582,000	13,123,000	$ 22,984,000
Loss contingency, loss in period							$ 1,800,000
Gain on recovery of fraudulent funds transfer	$ 1,800,000					0		0	$ 1,800,000	$ 0
Gensaic, Inc
Loss Contingencies [Line Items]
Payments to acquire investment			$ 5,100,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Loss Contingencies [Line Items]
Advance written notice required to terminate agreement									90 days
Northwestern University \| License Agreement
Loss Contingencies [Line Items]
Upfront non-creditable one-time license issuance fee payment					$ 75,000
Annual license maintenance fee payable					20,000
Consideration payable for rights grant					$ 5,300,000
Royalty obligation period					10 years
Minimum number of product covered under license agreement \| product					1
AstraZeneca
Loss Contingencies [Line Items]
Upfront cash payment				$ 5,000,000
Shares issued in license agreement				$ 7,300,000
Days immediately preceding the execution date				30 days
License agreement milestone payments (up to)				$ 203,000,000
First payment due upon completion of first phase				$ 3,000,000
Gensaic, Inc \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Loss Contingencies [Line Items]
License agreement milestone payments (up to)			452,000,000
Research plan and budget, expected costs		$ 3,500,000	$ 3,000,000
Prepaid expenses and other current assets						1,000,000			$ 1,000,000		$ 1,000,000
Research and development						$ 0		$ 600,000
Developmental milestone approvals, number of products (at least) \| product			3